Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance
Helen R Stagg,Graham H Bothamley,Jennifer A Davidson,Heinke Kunst,Maeve K Lalor,Marc C Lipman,Miranda G Loutet,Stefan Lozewicz,Tehreem Mohiyuddin,Aula Abbara,Eliza Alexander,Helen Booth,Dean D Creer,Ross J Harris,Onn Min Kon,Michael R Loebinger,Timothy D McHugh,Heather J Milburn,Paramita Palchaudhuri,Patrick P J Phillips,Erik Schmok,Lucy Taylor,Ibrahim Abubakar,London INH-R TB study group,Lucy V Baker,Jessica C Barrett,Helen Burgess,Catherine Cosgrove,Anne Dunleavy,Marie Francis,Urmi Gupta,Shahid Hamid,Brigitte M Haselden,Emma Holden,Vanessa Kahr,William Lynn,Felicity M Perrin,Ananna Rahman,Mohammad R Soobratty
DOI: https://doi.org/10.1183/13993003.00982-2019
2019-10-10
Abstract:Introduction: 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid (H)-resistant (Hr) tuberculosis recommend a four-drug regimen: rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx), with or without H ([H]RZE-Lfx). This is used once Hr is known, such that patients complete 6 months of Lfx (≥6[H]RZE-6Lfx). This cohort study assessed the impact of fluoroquinolones (Fq) on treatment effectiveness, accounting for Hr mutations and degree of phenotypic resistance. Methods: This was a retrospective cohort study of 626 Hr tuberculosis patients notified in London, 2009-2013. Regimens were described and logistic regression undertaken of the association between regimen and negative regimen-specific outcomes (broadly, death due to tuberculosis, treatment failure or disease recurrence). Results: Of 594 individuals with regimen information, 330 (55.6%) were treated with (H)RfZE (Rf=rifamycins) and 211 (35.5%) with (H)RfZE-Fq. The median overall treatment period was 11.9 months and median Z duration 2.1 months. In a univariable logistic regression model comparing (H)RfZE with and without Fqs, there was no difference in the odds of a negative regimen-specific outcome (baseline (H)RfZE, cluster-specific odds ratio 1.05 (95% CI 0.60-1.82), p=0.87; cluster NHS trust). Results varied minimally in a multivariable model. This odds ratio dropped (0.57, 95% CI 0.14-2.28) when Hr genotype was included, but this analysis lacked power (p=0.42). Conclusions: In a high-income setting, we found a 12-month (H)RfZE regimen with a short Z duration to be similarly effective for Hr tuberculosis with or without a Fq. This regimen may result in fewer adverse events than the WHO recommendations.